10 key facts about PMOS — the new name of PCOS

1.What is PMOS?

PMOS (Polyendocrine Metabolic Ovarian Syndrome) is the new name for PCOS, officially renamed on May 12, 2026 by a global consensus published in The Lancet. The word "polycystic" was dropped because the structures are follicles, not cysts. The disease itself has not changed.

Source: The Lancet, May 12, 2026

2.What's the difference between PCOS and PMOS?

None clinically. PMOS is simply the new name for PCOS. Diagnostic criteria (Rotterdam 2003, updated ESHRE 2023) are unchanged. The new name reflects that the condition is endocrine, metabolic, dermatological and mental — not solely ovarian.

Source: Endocrine Society, 2026

3.How is PMOS diagnosed in 2026?

It requires at least 2 of 3 Rotterdam criteria: irregular ovulation, clinical or biochemical hyperandrogenism, and either polycystic ovarian morphology on ultrasound or elevated AMH. Since 2023, AMH can replace ultrasound in adults.

Source: Monash International Guideline 2023

4.What are the 4 PMOS phenotypes (Rotterdam)?

Phenotype A (full): all 3 criteria — most severe. Phenotype B: ovulatory dysfunction + hyperandrogenism. Phenotype C (ovulatory): hyperandrogenism + polycystic morphology, regular periods. Phenotype D (non-hyperandrogenic): ovulatory dysfunction + polycystic morphology. The phenotype can evolve over time.

Source: ESHRE / Monash 2023

5.What is a normal HOMA-IR for someone with PMOS?

Below 1.0: optimal sensitivity. 1.0–1.9: normal. 1.9–2.9: early insulin resistance. Above 2.9: significant insulin resistance (US ADA threshold). The French threshold is 2.5. In PMOS, values ≥ 2.5 are linked to metabolic complications even at normal weight.

Source: Detailed HOMA-IR calculator

6.Are GLP-1 drugs like Ozempic effective for PMOS?

2025 evidence is strong but off-label. Tirzepatide produced -20.2% weight loss. Semaglutide produced -13.7%. Prescriptions of GLP-1 among women with PCOS rose from 2.4% (2021) to 17.6% (2025). No regulatory approval has been granted specifically for PMOS.

Source: Truveta, 2025

7.Can men have PMOS?

No, current consensus keeps the term "ovarian" in the name. However, fathers, brothers and sons of women with PMOS show high rates of insulin resistance and prediabetes. This suggests a shared genetic-metabolic phenotype. Research continues.

Source: STAT News, April 1, 2026

8.Inositol or metformin — which is better?

Comparable efficacy on insulin resistance and ovulation. A 2023 meta-analysis of 26 randomized trials found myo-inositol caused 84% fewer side effects than metformin. Many specialists combine both for severe cases (88% restoration of menstrual cycles).

Source: Meta-analysis 2023, 26 RCTs

9.Does PMOS go away after menopause?

No. Androgen-related symptoms (hirsutism, acne, hair loss) often decrease. But cardiometabolic risk (type 2 diabetes, dyslipidemia, hypertension, cardiovascular events) persists and may increase after menopause. Lifelong follow-up is recommended.

Source: Endocrine Society 2024

10.Is PMOS recognized as a disability in the US?

Not specifically. PMOS is not a designated disability under the ADA. However, its complications (chronic fatigue, infertility, severe depression) can qualify under workplace accommodations. The Social Security Administration recognizes endocrine disorders with significant functional impairment.

Source: ADA guidance 2024

General information. This page does not provide any diagnosis and does not replace a medical consultation. For any unusual or concerning symptom, consult a healthcare professional.